Report Synopsis
Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies’ commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater diversity of commercialization build-out models. These new dynamics greatly change how companies should be building models of commercialization that also has vast implications for potential BD partnerships. The solution to ‘build versus buy’ is no longer driven by the size, scale, and cost of a sales force leading to outdated product P&L’s. However, a hybrid solution that a partial build plus skilled, experienced contractors plus CSO for sales reps will be the optimal solution. This hybrid model could allow for greater biosimilar uptake and more efficient uptake.
Global market for Biosimilars is dominated by Oncology, estimated at US$5.4 billion (38.6% share) in 2020, which is anticipated to post the slowest CAGR of 29% between 2020 and 2026 and reach a projected US$24.8 billion by 2026.
Research Findings & Coverage
- Global Biosimilars market is analyzed in this report with respect to key product types and major therapeutic areas
- The study exclusively analyzes the market for each product type and therapeutic area of Biosimilars by all major geographic regions/countries globally
- mAbs - All the Rage in Biosimilars’ New Wave
- Patent Expirations of Major Biologics Leads Way for Biosimilars
- Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation
- Availability of Biosimilar May Affect Biologic Drug Pricing
- Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
- Major companies profiled - 36
- The industry guide includes the contact details for 155 companies
Product Outline
The report analyzes the market for the following key product types of Biosimilars:
- Monoclonal Antibodies (mAB)
- Erythropoietin (EPO)
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Insulin
- Others (includes Interferons, Follitropins, Recombinant Proteins etc.)
- Therapeutic areas of Biosimilars analyzed in this study comprise the following:
- Oncology
- Autoimmune Disorders
- Blood Disorders
- Growth Hormone Deficiency
- Others (includes Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.)
Analysis Period, Units and Growth Rates
- The report reviews, analyzes and projects the global Biosimilars market for the period 2017-2026 in terms of US$ and the compound annual growth rates (CAGRs) projected from 2019 through 2026
Geographic Coverage
- North America (The United States, Canada and Mexico)
- Europe (Germany, the United Kingdom, France, Spain, Italy and Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea and Rest of Asia-Pacific)
- Rest of World (Brazil, Israel and Other Rest of World)
Table of Contents
PART A: GLOBAL MARKET PERSPECTIVE
1. INTRODUCTION
1.1 Product Outline
1.1.1 Biosimilars Defined
1.1.2 Backdrop
1.1.3 The Biologics Price Competition and Innovation Act (BPCI Act)
1.1.3.1 Data Exclusivity
1.1.4 Steps Involved in Biosimilar Synthesis
1.1.5 Key Regulatory Authorization Pathway - Synopsis
1.1.6 Biosimilars Types
1.1.6.1 Monoclonal Antibodies (mAB or moAB)
1.1.6.1.1 Production Process
1.1.6.1.1.1 Hybridoma Cell Production
1.1.6.1.2 Therapeutic Applications
1.1.6.2 Erythropoietin (EPO)
1.1.6.2.1 Functions of EPO
1.1.6.2.2 Mechanism of Action
1.1.6.2.3 Synthesis and Regulation
1.1.6.2.4 Uses in Medicine
1.1.6.3 Granulocyte Colony-Stimulating Factor (G-CSF)
1.1.6.3.1 Biological Function
1.1.6.3.2 Genetics
1.1.6.3.3 Use in Therapeutics
1.1.6.4 Insulin
1.1.6.4.1 Biosimilar Insulin
1.1.6.4.2 The Complexity in Producing Biosimilar Insulin
1.1.6.4.3 Biosimilar Insulins and the Regulatory Environment Surrounding Them
1.1.6.4.4 The Market for Biosimilar Insulins
1.1.6.5 Interferons
1.1.6.5.1 Interferon Categorization
1.1.6.5.2 Functions of Interferons
1.1.6.5.3 Interferon Alfa
1.1.6.5.4 Interferon Beta-1a
1.1.6.5.5 Interferon Gamma
1.1.6.6 Human Growth Hormone
1.1.6.6.1 Recombinant Human Growth Hormone
1.1.6.6.2 Managing Growth Disorders Using Recombinant Human Growth Hormone Biosimilars
1.1.6.7 Other Biosimilars
1.1.7 Biosimilars Therapeutic Areas
1.1.7.1 Oncology
1.1.7.1.1 Biosimilar G-CSF
1.1.7.2 Autoimmune Diseases
1.1.7.3 Blood Disorders
1.1.7.4 Growth Hormone Deficiency (GHD)
1.1.7.4.1 Growth Hormone Deficiency in Children
1.1.7.5 Infectious Diseases
1.1.7.5.1 Treatment of Infectious Diseases
2. REGULATORY LANDSCAPE
2.1 The United States
2.1.1 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
2.1.2 Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product
2.1.3 Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
2.1.4 FDA Issues New Regulatory Updates in 2020
2.2 European
2.3 The World Health Organization (WHO)
2.4 Canada
2.5 South Korea
2.6 China
2.7 India
2.8 Japan
2.9 Mexico
2.10 Brazil
2.11 Argentina
3. KEY MARKET TRENDS
3.1 mAbs - All The Rage In Biosimilars’ New Wave
3.1.1 The Buildup to the Biosimilar Industry
3.1.2 Biosimilars of mAbs Approved: A Sneak Preview
3.2 Patent Expirations of Major Biologics Leads Way for Biosimilars
3.3 Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation
3.4 Availability of Biosimilar May Affect Biologic Drug Pricing
3.5 Asia-Pacific Witnessing a Boom of Biosimilars
4. RECENT BIOSIMILARS APPROVALS
5. KEY GLOBAL PLAYERS
- Amgen Inc. (The United States)
- AXXO GmbH (Germany)
- BIOCAD (Russia)
- Biogen, Inc. (The United States)
- Bioton S.A. (Poland)
- C.H. Boehringer Sohn AG & Co., KG. (Germany)
- Coherus Biosciences (The United States)
- Creative BioMart (The United States)
- Dong-A Socio Group (South Korea)
- Dr. Reddy's Laboratories Ltd. (India)
- Eli Lilly and Company (The United States)
- Genor Biopharma Co., Ltd. (China)
- Hetero Drugs Limited (India)
- Insud Pharma SL (Spain)
- mAbxience SA (Spain)
- Intas Pharmaceuticals Ltd. (India)
- Kashiv Biosciences LLC (The United States)
- LG Chem (South Korea)
- Lupin Limited (India)
- Mylan, Inc (The United States)
- Nippon Kayaku Co., Ltd. (Japan)
- Pfizer, Inc. (The United States)
- Reliance Life Sciences Pvt. Ltd. (India)
- Sandoz International GmbH (Germany)
- Shanghai Henlius Biotech, Inc. (China)
- STADA Arzneimittel AG (Germany)
- Teva Pharmaceutical Industries Limited (Israel)
- Wockhardt Limited (India)
6. KEY BUSINESS AND PRODUCT TRENDS
- AbbVie Inc and Frontier Collaborate on Novel Therapies and E3 Degraders
- Eli Lilly and UHG Collaborate on Bamlanivimab (LY-CoV555) Antibody Study
- Merck Receives FDA Review Acceptance for KEYTRUDA® (pembrolizumab) Plus Chemotherapy
- Samsung Bioepis and Biogen File U.S FDA Acceptance of SB11 Biosimilar
- EMA Approves Roche’s Xofluza® Biosimilar
- Genor’s New Drug Application for GB242 Infliximab Biosimilar is Under Review by NMPA
- NeuClone Discloses it’s Stelara® Biosimilar Candidate Clinical Trials
- FDA Approval for Anti-IL-4Rα Monoclonal Antibody
- Pfizer’s NYVEPRIA™ Biosimilar Receives FDA Approval
- Biocon Ltd Establishes Biosimilar Plant in India
- Boehringer Acquires Northern Biologics, Inc
- Biocon Ltd. and Mylan N.V Unveils Fulphila® Biosimilar
- mAbxience Establishes New Biosimilar Antibody Plant in Argentina
- CHMP Recommends RUXIENCE™ Biosimilar
- FDA Approval for ABP 798, a Biosimilar Candidate to Rituxan®
- Amgen Receives FDA Approval for its AVSOLA™ (Infliximab-axxq) Biosimilar Antibody
- 3SBio, Inc and Verseau Agree on Monoclonal Antibody Development - VTX-0811
- Boehringer Ingelheim Discloses GioTag Study Results
- Dr. Reddy’s Lab Unveils Versavo® Biosimilar
- Allergan and Gedeon Receive FDA Approval for VRAYLAR® Drug Use
- Samsung Bioepis Signs Biosimilars Development and Marketing Agreement with C-Bridge Capital
- Biosimilar Association of Samsung Bioepis and 3SBio
- Kashiv Pharma Renamed as KashivBioSciences Post Acquiring Adello Biologics
- Intas Unveils New Pegylated G-CSF Biosimilar in Europe
- Japanese Release of Trastuzumab and Agalsidase Beta Biosimilar
- Epoetin Alfa and Pegfilgrastim Biosimilars Now Accessible In the US at Considerable Concession
- Biosimilars of Insulin Glargine Introduced in South Korea and the UK
- CNDA Accepted Review of Adalimumab Biosimilar
- Filgrastim Biosimilar Application Submitted to the US FDA
- European Commercial Release of Amgevita and Imraldi
- MHLW of Japan Received Approval Application for Dual Darbepoetin Alfa Copy Biologics
- Evaluation of Adalimumab Biosimilar SB5 by USFDA
- Acceptance of Approval Application by CFDA for Adalimumab Biosimilar
- Review Acceptance for MabionCD20 by EMA and Rituxan Expanded the Therapeutic Range
- Dr Reddy’s Introduces Hervycta, A Trastuzumab Biosimilar in India
- Apotex Influence Canadian Biosimilar Market
- Resubmission of Marketing Approval of Biosimilar Rituximab to FDA by Celltrion
- Refusal of Trastuzumab and Rituximab Biosimilars Approval Applications by FDA
- Rejection of Rituximab and Trastuzumab of Celltrion/Teva by FDA
- Amgen and Allergan Authorize ABP 980 Biosimilar
- OntruzantTrastuzumab Biosimilar Released in the UK
- Commercialization of Trastuzumab Biosimilar in South Korea By Daewoong
- Commercial Release of Adalimumab Biosimilar in India by Hetero
- Production of Denosumab Biosimilar in Australia
7. GLOBAL MARKET OVERVIEW
7.1 Global Biosimilars Market Overview by Product Type
7.1.1 Global Biosimilars Product Types Market Overview by Geographic Region
7.1.1.1 Monoclonal Antibodies
7.1.1.2 Erythropoietin
7.1.1.3 G-CSF
7.1.1.4 Insulin
7.1.1.5 Other Product Types
7.2 Global Biosimilars Market Overview by Therapeutic Area
7.2.1 Global Biosimilars Therapeutic Area Market Overview by Geographic Region
7.2.1.1 Oncology
7.2.1.2 Autoimmune Disorders
7.2.1.3 Blood Disorders
7.2.1.4 Growth Hormone Deficiency
7.2.1.5 Other Therapeutic Areas
PART B: REGIONAL MARKET PERSPECTIVE
REGIONAL MARKET OVERVIEW
8. EUROPE
8.1 European Biosimilars Market Overview by Geographic Region
8.2 European Biosimilars Market Overview by Product Type
8.2.1 European Biosimilars Product Types Market Overview by Geographic Region
8.2.1.1 Monoclonal Antibodies
8.2.1.2 Erythropoietin
8.2.1.3 G-CSF
8.2.1.4 Insulin
8.2.1.5 Other Product Types
8.3 European Biosimilars Market Overview by Therapeutic Area
8.3.1 European Biosimilars Therapeutic Area Market Overview by Geographic Region
8.3.1.1 Oncology
8.3.1.2 Autoimmune Disorders
8.3.1.3 Blood Disorders
8.3.1.4 Growth Hormone Deficiency
8.3.1.5 Other Therapeutic Areas
8.4 Major Market Players
- AXXO GmbH (Germany)
- BIOCAD (Russia)
- Bioton S.A. (Poland)
- C.H. Boehringer Sohn AG & Co., KG. (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fresenius Kabi AG (Germany)
- Insud Pharma SL (Spain)
- mAbxience SA (Spain)
- Sandoz International GmbH (Germany)
- STADA Arzneimittel AG (Germany)
8.5 Country-wise analysis of European Biosimilars Market
8.5.1 Germany
8.5.1.1 German Biosimilars Market Overview by Product Type
8.5.1.2 German Biosimilars Market Overview by Therapeutic Area
8.5.2 United Kingdom
8.5.2.1 United Kingdom Biosimilars Market Overview by Product Type
8.5.2.2 United Kingdom Biosimilars Market Overview by Therapeutic Area
8.5.3 France
8.5.3.1 French Biosimilars Market Overview by Product Type
8.5.3.2 French Biosimilars Market Overview by Therapeutic Area
8.5.4 Spain
8.5.4.1 Spanish Biosimilars Market Overview by Product Type
8.5.4.2 Spanish Biosimilars Market Overview by Therapeutic Area
8.5.5 Italy
8.5.5.1 Italian Biosimilars Market Overview by Product Type
8.5.5.2 Italian Biosimilars Market Overview by Therapeutic Area
8.5.6 Rest of Europe
8.5.6.1 Rest of Europe Biosimilars Market Overview by Product Type
8.5.6.2 Rest of Europe Biosimilars Market Overview by Therapeutic Area
9. NORTH AMERICA
9.1 North American Biosimilars Market Overview by Geographic Region
9.2 North American Biosimilars Market Overview by Product Type
9.2.1 North American Biosimilars Product Types Market Overview by Geographic Region
9.2.1.1 Monoclonal Antibodies
9.2.1.2 Erythropoietin
9.2.1.3 G-CSF
9.2.1.4 Insulin
9.2.1.5 Other Product Types
9.3 North American Biosimilars Market Overview by Therapeutic Area
9.3.1 North American Biosimilars Therapeutic Area Market Overview by Geographic Region
9.3.1.1 Oncology
9.3.1.2 Autoimmune Disorders
9.3.1.3 Blood Disorders
9.3.1.4 Growth Hormone Deficiency
9.3.1.5 Other Therapeutic Areas
9.4 Major Market Players
- Amgen Inc. (The United States)
- Apotex, Inc. (Canada)
- Biogen, Inc. (The United States)
- Coherus BioSciences (The United States)
- Creative Biomart, Inc. (The United States)
- Eli Lilly and Company (The United States)
- Kashiv Biosciences LLC (The United States)
- Mylan, Inc (The United States)
- Pfizer, Inc. (The United States)
- Probiomed S.A. De C.V (Mexico)
9.5 Country-wise Analysis of North American Biosimilars Market
9.5.1 The United States
9.5.1.1 United States Biosimilars Market Overview by Product Type
9.5.1.2 United States Biosimilars Market Overview by Therapeutic Area
9.5.2 Canada
9.5.2.1 Canadian Biosimilars Market Overview by Product Type
9.5.2.2 Canadian Biosimilars Market Overview by Therapeutic Area
9.5.3 Mexico
9.5.3.1 Mexican Biosimilars Market Overview by Product Type
9.5.3.2 Mexican Biosimilars Market Overview by Therapeutic Area
10. ASIA-PACIFIC
10.1 Asia-Pacific Biosimilars Market Overview by Geographic Region
10.2 Asia-Pacific Biosimilars Market Overview by Product Type
10.2.1 Asia-Pacific Biosimilars Product Types Market Overview by Geographic Region
10.2.1.1 Monoclonal Antibodies
10.2.1.2 Erythropoietin
10.2.1.3 G-CSF
10.2.1.4 Insulin
10.2.1.5 Other Product Types
10.3 Asia-Pacific Biosimilars Market Overview by Therapeutic Area
10.3.1 Asia-Pacific Biosimilars Therapeutic Area Market Overview by Geographic Region
10.3.1.1 Oncology
10.3.1.2 Autoimmune Disorders
10.3.1.3 Blood Disorders
10.3.1.4 Growth Hormone Deficiency
10.3.1.5 Other Therapeutic Areas
10.4 Major Market Players
- Celltrion, Inc. (South Korea)
- Dong-A Socio Group (South Korea)
- Dr. Reddy's Laboratories Ltd. (India)
- Genor Biopharma Co., Ltd. (China)
- Hetero Drugs Limited (India)
- Intas Pharmaceuticals Ltd (India)
- LG Chem (South Korea)
- Lupin Limited (India)
- Nippon Kayaku Co., Ltd. (Japan)
- Reliance Life Sciences Pvt., Ltd. (India)
- Samsung Biologics Co., Ltd. (South Korea)
- Shanghai Henlius Biotech, Inc. (China)
- Wockhardt Limited (India)
- Zydus Cadila (India)
10.5 Country-wise Analysis of Asia-Pacific Biosimilars Market
10.5.1 China
10.5.1.1 Chinese Biosimilars Market Overview by Product Type
10.5.1.2 Chinese Biosimilars Market Overview by Therapeutic Area
10.5.2 India
10.5.2.1 Indian Biosimilars Market Overview by Product Type
10.5.2.2 Indian Biosimilars Market Overview by Therapeutic Area
10.5.3 Japan
10.5.3.1 Japanese Biosimilars Market Overview by Product Type
10.5.3.2 Japanese Biosimilars Market Overview by Therapeutic Area
10.5.4 South Korea
10.5.4.1 South Korean Biosimilars Market Overview by Product Type
10.5.4.2 South Korean Biosimilars Market Overview by Therapeutic Area
10.5.5 Rest of Asia-Pacific
10.5.5.1 Rest of Asia-Pacific Biosimilars Market Overview by Product Type
10.5.5.2 Rest of Asia-Pacific Biosimilars Market Overview by Therapeutic Area
11. REST OF WORLD
11.1 Rest of World Biosimilars Market Overview by Geographic Region
11.2 Rest of World Biosimilars Market Overview by Product Type
11.2.1 Rest of World Biosimilars Product Types Market Overview by Geographic Region
11.2.1.1 Monoclonal Antibodies
11.2.1.2 Erythropoietin
11.2.1.3 G-CSF
11.2.1.4 Insulin
11.2.1.5 Other Product Types
11.3 Rest of World Biosimilars Market Overview by Therapeutic Area
11.3.1 Rest of World Biosimilars Therapeutic Area Market Overview by Geographic Region
11.3.1.1 Oncology
11.3.1.2 Autoimmune Disorders
11.3.1.3 Blood Disorders
11.3.1.4 Growth Hormone Deficiency
11.3.1.5 Other Therapeutic Areas
11.4 Major Market Players
- AMEGA Biotech (Argentina)
- Teva Pharmaceutical Industries Limited (Israel)
11.5 Country-wise Analysis of Rest of World Biosimilars Market
11.5.1 Brazil
11.5.1.1 Brazilian Biosimilars Market Overview by Product Type
11.5.1.2 Brazilian Biosimilars Market Overview by Therapeutic Area
11.5.2 Israel
11.5.2.1 Israeli Biosimilars Market Overview by Product Type
11.5.2.2 Israeli Biosimilars Market Overview by Therapeutic Area
11.5.3 Other Countries
11.5.3.1 Other Countries Biosimilars Market Overview by Product Type
11.5.3.2 Other Countries Biosimilars Market Overview by Therapeutic Area
PART C: GUIDE TO THE INDUSTRY
1. North America
2. Europe
3. Asia-Pacific
4. Rest Of World
PART D: ANNEXURE
1. Research Methodology
2. Feedback
Charts & Graphs
PART A: GLOBAL MARKET PERSPECTIVE
Chart 1: Global Biosimilars Market (2020 & 2026) by Geographic Region
Chart 2: Global Biosimilars Market (2020 & 2026) by Product Type
Chart 3: Global Biosimilars Market (2020 & 2026) by Therapeutic Areas
Chart 4: Global Biosimilars Market Analysis (2017-2026) in USD Million
Chart 5: Global Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 6: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 7: Global Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in USD Million
Chart 8: Glance at 2017, 2020 and 2026 Global Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
Chart 9: Global Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
Chart 10: Glance at 2017, 2020 and 2026 Global Biosimilar Erythropoietin Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
Chart 11: Global Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
Chart 12: Glance at 2017, 2020 and 2026 Global Biosimilar G-CSF Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
Chart 13: Global Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
Chart 14: Glance at 2017, 2020 and 2026 Global Biosimilar Insulin Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
Chart 15: Global Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
Chart 16: Glance at 2017, 2020 and 2026 Global Other Biosimilar Products Types Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
Chart 17: Global Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 18: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Chart 19: Global Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
Chart 20: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Oncology by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
Chart 21: Global Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
Chart 22: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
Chart 23: Global Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
Chart 24: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
Chart 25: Global Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
Chart 26: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
Chart 27: Global Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
Chart 28: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
PART B: REGIONAL MARKET PERSPECTIVE
Chart 29: Global Biosimilars Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in USD Million
Chart 30: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
REGIONAL MARKET OVERVIEW
EUROPE
Chart 31: European Biosimilars Market Analysis (2017-2026) in USD Million
Chart 32: European Biosimilars Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in USD Million
Chart 33: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 34: European Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 35: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 36: European Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in USD Million
Chart 37: Glance at 2017, 2020 and 2026 European Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 38: European Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
Chart 39: Glance at 2017, 2020 and 2026 European Biosimilar Erythropoietin Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 40: European Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
Chart 41: Glance at 2017, 2020 and 2026 European Biosimilar G-CSF Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 42: European Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
Chart 43: Glance at 2017, 2020 and 2026 European Biosimilar Insulin Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 44: European Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
Chart 45: Glance at 2017, 2020 and 2026 European Other Biosimilar Products Types Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 46: European Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 47: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Chart 48: European Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
Chart 49: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Oncology by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 50: European Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
Chart 51: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 52: European Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
Chart 53: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 54: European Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
Chart 55: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Chart 56: European Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
Chart 57: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
Germany
Chart 58: German Biosimilars Market Analysis (2017-2026) in USD Million
Chart 59: German Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 60: Glance at 2017, 2020 and 2026 German Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 61: German Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 62: Glance at 2017, 2020 and 2026 German Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
United Kingdom
Chart 63: United Kingdom Biosimilars Market Analysis (2017-2026) in USD Million
Chart 64: United Kingdom Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 65: Glance at 2017, 2020 and 2026 United Kingdom Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 66: United Kingdom Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 67: Glance at 2017, 2020 and 2026 United Kingdom Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
France
Chart 68: French Biosimilars Market Analysis (2017-2026) in USD Million
Chart 69: French Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 70: Glance at 2017, 2020 and 2026 French Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 71: French Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 72: Glance at 2017, 2020 and 2026 French Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Spain
Chart 73: Spanish Biosimilars Market Analysis (2017-2026) in USD Million
Chart 74: Spanish Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 75: Glance at 2017, 2020 and 2026 Spanish Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 76: Spanish Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 77: Glance at 2017, 2020 and 2026 Spanish Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Italy
Chart 78: Italian Biosimilars Market Analysis (2017-2026) in USD Million
Chart 79: Italian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 80: Glance at 2017, 2020 and 2026 Italian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 81: Italian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 82: Glance at 2017, 2020 and 2026 Italian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Rest of Europe
Chart 83: Rest of Europe Biosimilars Market Analysis (2017-2026) in USD Million
Chart 84: Rest of Europe Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 85: Glance at 2017, 2020 and 2026 Rest of Europe Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 86: Rest of Europe Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 87: Glance at 2017, 2020 and 2026 Rest of Europe Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
NORTH AMERICA
Chart 88: North American Biosimilars Market Analysis (2017-2026) in USD Million
Chart 89: North American Biosimilars Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in USD Million
Chart 90: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) by Geographic Region - United States, Canada and Mexico
Chart 91: North American Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 92: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 93: North American Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in USD Million
Chart 94: Glance at 2017, 2020 and 2026 North American Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - United States, Canada and Mexico
Chart 95: North American Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US$ Million
Chart 96: Glance at 2017, 2020 and 2026 North American Biosimilar Erythropoietin Market Share (%) by Geographic Region - United States, Canada and Mexico
Chart 97: North American Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US$ Million
Chart 98: Glance at 2017, 2020 and 2026 North American Biosimilar G-CSF Market Share (%) by Geographic Region - United States, Canada and Mexico
Chart 99: North American Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US$ Million
Chart 100: Glance at 2017, 2020 and 2026 North American Biosimilar Insulin Market Share (%) by Geographic Region - United States, Canada and Mexico
Chart 101: North American Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US$ Million
Chart 102: Glance at 2017, 2020 and 2026 North American Other Biosimilar Products Types Market Share (%) by Geographic Region - United States, Canada and Mexico
Chart 103: North American Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 104: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Chart 105: North American Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - United States, Canada and Mexico in US$ Million
Chart 106: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Oncology by Geographic Region - United States, Canada and Mexico
Chart 107: North American Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - United States, Canada and Mexico in US$ Million
Chart 108: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - United States, Canada and Mexico
Chart 109: North American Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - United States, Canada and Mexico in US$ Million
Chart 110: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Blood Disorders by Geographic Region - United States, Canada and Mexico
Chart 111: North American Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - United States, Canada and Mexico in US$ Million
Chart 112: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - United States, Canada and Mexico
Chart 113: North American Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - United States, Canada and Mexico in US$ Million
Chart 114: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - United States, Canada and Mexico
The United States
Chart 115: United States Biosimilars Market Analysis (2017-2026) in USD Million
Chart 116: United States Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 117: Glance at 2017, 2020 and 2026 United States Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 118: United States Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 119: Glance at 2017, 2020 and 2026 United States Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Canada
Chart 120: Canadian Biosimilars Market Analysis (2017-2026) in USD Million
Chart 121: Canadian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 122: Glance at 2017, 2020 and 2026 Canadian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 123: Canadian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 124: Glance at 2017, 2020 and 2026 Canadian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Mexico
Chart 125: Mexican Biosimilars Market Analysis (2017-2026) in USD Million
Chart 126: Mexican Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 127: Glance at 2017, 2020 and 2026 Mexican Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 128: Mexican Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 129: Glance at 2017, 2020 and 2026 Mexican Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
ASIA-PACIFIC
Chart 130: Asia-Pacific Biosimilars Market Analysis (2017-2026) in USD Million
Chart 131: Asia-Pacific Biosimilars Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in USD Million
Chart 132: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 133: Asia-Pacific Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 134: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 135: Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in USD Million
Chart 136: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 137: Asia-Pacific Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
Chart 138: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar Erythropoietin Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 139: Asia-Pacific Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
Chart 140: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar G-CSF Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 141: Asia-Pacific Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
Chart 142: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar Insulin Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 143: Asia-Pacific Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
Chart 144: Glance at 2017, 2020 and 2026 Asia-Pacific Other Biosimilar Products Types Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 145: Asia-Pacific Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 146: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Chart 147: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
Chart 148: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Oncology by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 149: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
Chart 150: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 151: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
Chart 152: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Blood Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 153: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
Chart 154: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
Chart 155: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
Chart 156: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
China
Chart 157: Chinese Biosimilars Market Analysis (2017-2026) in USD Million
Chart 158: Chinese Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 159: Glance at 2017, 2020 and 2026 Chinese Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 160: Chinese Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 161: Glance at 2017, 2020 and 2026 Chinese Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
India
Chart 162: Indian Biosimilars Market Analysis (2017-2026) in USD Million
Chart 163: Indian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 164: Glance at 2017, 2020 and 2026 Indian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 165: Indian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 166: Glance at 2017, 2020 and 2026 Indian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Japan
Chart 167: Japanese Biosimilars Market Analysis (2017-2026) in USD Million
Chart 168: Japanese Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 169: Glance at 2017, 2020 and 2026 Japanese Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 170: Japanese Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 171: Glance at 2017, 2020 and 2026 Japanese Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
South Korea
Chart 172: South Korean Biosimilars Market Analysis (2017-2026) in USD Million
Chart 173: South Korean Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 174: Glance at 2017, 2020 and 2026 South Korean Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 175: South Korean Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 176: Glance at 2017, 2020 and 2026 South Korean Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Rest of Asia-Pacific
Chart 177: Rest of Asia-Pacific Biosimilars Market Analysis (2017-2026) in USD Million
Chart 178: Rest of Asia-Pacific Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 179: Glance at 2017, 2020 and 2026 Rest of Asia-Pacific Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 180: Rest of Asia-Pacific Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 181: Glance at 2017, 2020 and 2026 Rest of Asia-Pacific Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
REST OF WORLD
Chart 182: Rest of World Biosimilars Market Analysis (2017-2026) in USD Million
Chart 183: Rest of World Biosimilars Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in USD Million
Chart 184: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
Chart 185: Rest of World Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 186: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 187: Rest of World Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in USD Million
Chart 188: Glance at 2017, 2020 and 2026 Rest of World Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
Chart 189: Rest of World Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
Chart 190: Glance at 2017, 2020 and 2026 Rest of World Biosimilar Erythropoietin Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
Chart 191: Rest of World Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
Chart 192: Glance at 2017, 2020 and 2026 Rest of World Biosimilar G-CSF Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
Chart 193: Rest of World Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
Chart 194: Glance at 2017, 2020 and 2026 Rest of World Biosimilar Insulin Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
Chart 195: Rest of World Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
Chart 196: Glance at 2017, 2020 and 2026 Rest of World Other Biosimilar Products Types Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
Chart 197: Rest of World Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 198: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Chart 199: Rest of World Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - Brazil, Israel and Other Countries in US$ Million
Chart 200: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Oncology by Geographic Region - Brazil, Israel and Other Countries
Chart 201: Rest of World Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - Brazil, Israel and Other Countries in US$ Million
Chart 202: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Brazil, Israel and Other Countries
Chart 203: Rest of World Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - Brazil, Israel and Other Countries in US$ Million
Chart 204: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Brazil, Israel and Other Countries
Chart 205: Rest of World Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - Brazil, Israel and Other Countries in US$ Million
Chart 206: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Brazil, Israel and Other Countries
Chart 207: Rest of World Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - Brazil, Israel and Other Countries in US$ Million
Chart 208: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Brazil, Israel and Other Countries
Brazil
Chart 209: Brazilian Biosimilars Market Analysis (2017-2026) in USD Million
Chart 210: Brazilian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 211: Glance at 2017, 2020 and 2026 Brazilian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 212: Brazilian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 213: Glance at 2017, 2020 and 2026 Brazilian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Israel
Chart 214: Israeli Biosimilars Market Analysis (2017-2026) in USD Million
Chart 215: Israeli Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 216: Glance at 2017, 2020 and 2026 Israeli Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 217: Israeli Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 218: Glance at 2017, 2020 and 2026 Israeli Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Other Countries
Chart 219: Other Countries Biosimilars Market Analysis (2017-2026) in USD Million
Chart 220: Other Countries Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
Chart 221: Glance at 2017, 2020 and 2026 Other Countries Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
Chart 222: Other Countries Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
Chart 223: Glance at 2017, 2020 and 2026 Other Countries Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
Tables:
Table 1: Biosimilar Synonyms
Table 2: Comparison of Generics and Biosimilars
Table 3: List of the US and European Approved Biosimilars for Diabetes
Table 4: List of the US and European Approved Biosimilars for Oncology
Table 5: List of the US and European Approved Biosimilars for Autoimmune Disorders
Table 6: List of the US and European Approved Biosimilars for Blood Disorders
Table 7: List of the US and European Approved Biosimilars for Other Indications
Table 8: List of Leading Bioloigcs Containing mAbs, Year of Approval and Patent Expiry in Europe and the United States
Table 9: Global Biosimilar Approvals Since 2006: mAbs Occupy Major Share
Table 10: Biosimilars Pipeline by Company
Table 11: Biosimilars Approvals from 2018 to 2020
Samples
LOADING...
Companies Mentioned
- 3SBio, Inc
- AbbVie Inc
- Allergan
- AMEGA Biotech
- Amgen Inc.
- Apotex, Inc.
- AXXO GmbH
- BIOCAD
- Biocon Ltd
- Biogen, Inc.
- Bioton S.A.
- Boehringer
- Boehringer Ingelheim
- C.H. Boehringer Sohn AG & Co., KG.
- Celltrion, Inc.
- Coherus Biosciences
- Creative Biomart, Inc.
- Dong-A Socio Group
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Fresenius Kabi AG
- Gedeon
- Genor Biopharma Co., Ltd.
- Hetero Drugs Limited
- Insud Pharma SL
- Intas Pharmaceuticals Ltd.
- Kashiv Biosciences LLC
- LG Chem
- Lupin Limited
- mAbxience SA
- Merck
- Mylan, Inc
- NeuClone
- Nippon Kayaku Co., Ltd.
- Pfizer, Inc.
- Probiomed S.A. De C.V
- Reliance Life Sciences Pvt. Ltd.
- Roche
- Samsung Biologics Co., Ltd.
- Sandoz International GmbH
- Shanghai Henlius Biotech, Inc.
- STADA Arzneimittel AG
- Teva Pharmaceutical Industries Limited
- UHG
- Verseau
- Wockhardt Limited
- Zydus Cadila
